Archive · 7 Oct 2026
Sun Pharma Board to Consider ₹15,000 Crore NCD Issue
Sun Pharma plans to discuss raising money by issuing bonds called non-convertible debentures.
Its board is due to consider the plan on October 12, 2026.
The company could raise up to ₹15,000 crore through the proposed issue.
Reuters has reported that Sun Pharma took out a large bridge loan to help pay for buying Organon & Co.
Separately, Sun Pharma made a deal with LIB Therapeutics for a cholesterol medicine called lerodalcibep in markets outside the United States and China.
The deal includes payments and royalties for LIB Therapeutics.
Sun Pharma also reported its June-quarter profit and revenue.
Sun Pharmaceutical Industries’ board is scheduled to meet on October 12, 2026, to consider issuing non-convertible debentures.
The proposed listed, rated, unsecured and redeemable NCDs would be privately placed in one or more tranches, up to ₹15,000 crore.
Reuters, citing sources, reported that Sun Pharma arranged a nearly $12 billion, 18-month bridge loan to help finance its acquisition of Organon & Co.
The company recently agreed to license and commercialize lerodalcibep outside the United States and China, while LIB Therapeutics will receive milestone payments and royalties.
Sun Pharma reported June-quarter consolidated net profit of ₹2,894.79 crore and revenue from operations of ₹15,299.88 crore.
- Who
- Sun Pharmaceutical Industries and its board of directors.
- What
- The board will consider a private placement of listed, rated, unsecured, redeemable non-convertible debentures worth up to ₹15,000 crore.
- When
- The board meeting is scheduled for October 12, 2026.
- Where
- The announcement was made in a regulatory filing; the proposed NCDs would be issued through private placement.
- Why
- Reuters reported, citing sources, that a rupee-denominated debt sale is planned partly to fund a bridge loan used to finance the acquisition of Organon & Co.
Company rationale
Reported financing context
Purpose of the proposed debt issue
Company rationale
Sun Pharma’s filing says the board will consider an NCD issue of up to ₹15,000 crore but does not state its intended use.
Reported financing context
Reuters, citing sources, reported that a rupee-denominated debt sale is planned partly to fund a bridge loan used for the Organon acquisition.
- Proposed maximum issue
- ₹15,000 crore
- Board meeting
- October 12, 2026
- NCD placement
- Private placement, in one or more tranches
- Reported bridge loan
- Nearly $12 billion, with an 18-month term, according to Reuters sources
- Acquisition linked to loan
- Organon & Co.
- June-quarter consolidated net profit
- ₹2,894.79 crore, up 27%
- June-quarter revenue from operations
- ₹15,299.88 crore, compared with ₹13,851.4 crore a year earlier